留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

ETV1、FOXF1表达与胃肠间质瘤

刘东 朱长真 康维明

刘东, 朱长真, 康维明. ETV1、FOXF1表达与胃肠间质瘤[J]. 协和医学杂志, 2020, 11(5): 592-595. doi: 10.3969/j.issn.1674-9081.2020.05.015
引用本文: 刘东, 朱长真, 康维明. ETV1、FOXF1表达与胃肠间质瘤[J]. 协和医学杂志, 2020, 11(5): 592-595. doi: 10.3969/j.issn.1674-9081.2020.05.015
Dong LIU, Chang-zhen ZHU, Wei-ming KANG. Research Progress of ETV1 and FOXF1 in Gastrointestinal Stromal Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 592-595. doi: 10.3969/j.issn.1674-9081.2020.05.015
Citation: Dong LIU, Chang-zhen ZHU, Wei-ming KANG. Research Progress of ETV1 and FOXF1 in Gastrointestinal Stromal Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 592-595. doi: 10.3969/j.issn.1674-9081.2020.05.015

ETV1、FOXF1表达与胃肠间质瘤

doi: 10.3969/j.issn.1674-9081.2020.05.015
基金项目: 

希思科-豪森肿瘤研究基金 Y-HS2019-43

吴阶平医学基金 320.6750.19020

详细信息
    通讯作者:

    康维明  电话:010-69152215,E-mail:kangweiming@163.com

  • 中图分类号: R573

Research Progress of ETV1 and FOXF1 in Gastrointestinal Stromal Tumors

More Information
  • 摘要: 胃肠间质瘤(gastrointestinal stromal tumors,GISTs)是消化道最常见的间叶组织肿瘤,起源于消化道肌层Cajal细胞(interstitial cells of Cajal, ICC)或其同源干细胞,其发生多数与KIT或PDGFRA基因突变有关。GISTs的发病率、靶向治疗耐药率及术后复发率逐年升高,极大影响了患者预后,故寻找新的治疗方法已成为当前GISTs的研究热点。ETV1是转录因子ETS家族成员,可刺激KIT基因转录,KIT蛋白通过MEK-MAPK信号通路增强ETV1的表达,ETV1和KIT正反馈协同调节导致ICC/GISTs细胞内信号通路持续激活,从而促进肿瘤增殖。FOXF1在GISTs中呈特异性高表达, 可能与KIT和ETV1上游调节因子促进ICC/GISTs谱系特有基因表达有关。ETV1、FOXF1可能为GISTs的治疗提供新思路、新方向。本文就ETV1、FOXF1表达与GISTs的关系作一综述。
    利益冲突  无
  • [1] 崔宁宜, 王勇, 吕珂.小肠淋巴瘤和小肠间质瘤的超声征象及鉴别诊断[J].协和医学杂志, 2016, 7:342-346. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201605006
    [2] Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach[J]. Human Pathology, 2002, 33:459-465. doi:  10.1053/hupa.2002.123545
    [3] Dematteo RP, Ballman KV, Antonescu CR, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2009, 373:1097-1104. doi:  10.1016/S0140-6736(09)60500-6
    [4] Miettinen M, Monihan JM, Sarlomorikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases[J]. Am J Surg Pathol, 1999, 23:1109-1118. doi:  10.1097/00000478-199909000-00015
    [5] Sarlomorikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34[J]. Mod Pathol, 1998, 11:728-734. https://pubmed.ncbi.nlm.nih.gov/9720500/
    [6] 邓志勇, 李海, 张阳, 等.胃肠道间质瘤误诊12例临床病理特征分析[J].中国误诊学杂志, 2006, 6:2547-2548. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgwzxzz200613084
    [7] Zhu CZ, Liu D, Kang WM, et al. Ghrelin and gas-trointestinal stromal tumors[J]. World J Gastroentero, 2017, 23:1758-1763. doi:  10.3748/wjg.v23.i10.1758
    [8] Heinrich MC. PDGFRA activating mutations in gastmintest-inal stromal tumor[J]. Science, 2003, 299:708-710. doi:  10.1126/science.1079666
    [9] Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up[J]. Am J Surg Pathol, 2005, 29:1373-1381. doi:  10.1097/01.pas.0000172190.79552.8b
    [10] Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopatho-logic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up[J]. Am J Surg Pathol, 2006, 30:477-489. doi:  10.1097/00000478-200604000-00008
    [11] Vadakara J, von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies[J]. Hematol Oncol Clin North Am, 2013, 27:905-920. doi:  10.1016/j.hoc.2013.07.007
    [12] Gramza AW, Corless CL, Heinrich MC. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors[J]. Clin Cancer Res, 2009, 15:7510-7518. doi:  10.1158/1078-0432.CCR-09-0190
    [13] Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial[J]. Lancet, 2006, 368: 1329-1338. doi:  10.1016/S0140-6736(06)69446-4
    [14] Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science, 1998, 279: 577-580. doi:  10.1126/science.279.5350.577
    [15] Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors[J]. Gastroenterology, 2003, 125: 660-667. doi:  10.1016/S0016-5085(03)01046-1
    [16] Kurpios NA, Macneil L, Shepherd TG, et al. The Pea3 Ets transcription factor regulates differentiation of multipotent progenitor cells during mammary gland development[J]. Dev Biol, 2009, 325:106-121. doi:  10.1016/j.ydbio.2008.09.033
    [17] De LY, Baert JL, Chotteaulelievre A, et al. The Ets transcription factors of the PEA3 group: transcriptional regu-lators in metastasis[J]. BBA Rev Cancer, 2006, 1766:79-87.
    [18] Ordóñez JL, Osuna D, Herrero D, et al. Advances in Ewing's sarcoma research: Where are we now and what lies ahead?[J]. Cancer Res, 2009, 69:7140-7150. doi:  10.1158/0008-5472.CAN-08-4041
    [19] Jane-Valbuena J, Widlund HR, Perner S, et al. An Oncogenic Role for ETV1 in Melanoma[J]. Cancer Res, 2010, 70:2075-2084. doi:  10.1158/0008-5472.CAN-09-3092
    [20] Baker R, Kent CV, Silbermann RA, et al. Pea3 transcrip-tion factors and wnt1-induced mouse mammary neoplasia[J]. PLoS One, 2010, 5:e8854. doi:  10.1371/journal.pone.0008854
    [21] Vageli D, Ioannou MG, Koukoulis GK. Transcriptional activation of hTERT in breast carcinomas by the Her2-ER81-related pathway[J]. Oncol Res, 2009, 17:413-423. doi:  10.3727/096504009788912507
    [22] Oh S, Shin S, Janknecht R. ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors[J]. Biochimica et Biophysica Acta, 2012, 1826:1-12.
    [23] Jané-Valbuena J, Widlund HR, Perner S, et al. An Oncogenic Role for ETV1 in Melanoma[J]. Cancer Res, 2010, 70:2075-2084. doi:  10.1158/0008-5472.CAN-09-3092
    [24] Dwyer J, He LI, Dakang XU, et al. Transcriptional Regulation of Telomerase Activity[J]. Ann NY Acad Sci, 2010, 1114:36-47.
    [25] Goueli BS, Janknecht R. Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf[J]. Mol Cell Biol, 2004, 24:25-35. doi:  10.1128/MCB.24.1.25-35.2004
    [26] Ran L, Sirota I, Cao Z, et al. Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth[J]. Cancer Discov, 2015, 5:304-315. doi:  10.1158/2159-8290.CD-14-0985
    [27] Chi P, Chen Y, Zhang L, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours[J]. Nature, 2010, 467:849-853. doi:  10.1038/nature09409
    [28] 殷舞, 农涛, 黄顺荣, 等.胃肠间质瘤中ETV1的表达及意义[J].广东医学, 2017, 38:1358-1362. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gdyx201709014
    [29] Golson ML, Kaestner KH. Fox transcription factors: From development to disease[J]. Development, 2016, 143:4558-4570. doi:  10.1242/dev.112672
    [30] Lam EWF, Brosens JJ, Gomes AR, et al. Forkhead box proteins: tuning forks for transcriptional harmony[J]. Nat Rev Cancer, 2013, 13:482-495. doi:  10.1038/nrc3539
    [31] Wei HJ, Lo WC, Nickoloff JA, et al. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells[J]. Oncotarget, 2014, 5:9514-9529. doi:  10.18632/oncotarget.2413
    [32] Ran L, Chen Y, Sher J, et al. FOXF1 defines the core-regulatory circuitry in gastrointestinal stromal tumor (GIST)[J]. Cancer Discov, 2018, 8:234-251. doi:  10.1158/2159-8290.CD-17-0468
    [33] Szafranski P, Dharmadhikari AV, Wambach JA, et al. Two deletions overlapping a distant/r, FOXF1/r, enhancer unravel the role of lncRNA/r, LINC01081/r, in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins[J]. Am J Med Genet A, 2014, 164:2013-2019. doi:  10.1002/ajmg.a.36606
    [34] Tang CM, Lee TE, Syed SA, et al. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression[J]. Oncotarget, 2016, 7:78226-78241. doi:  10.18632/oncotarget.12909
  • 加载中
计量
  • 文章访问数:  129
  • HTML全文浏览量:  22
  • PDF下载量:  41
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-05-21
  • 刊出日期:  2020-09-30

目录

    /

    返回文章
    返回